Analysis and considerations on revision of instructions for traditional Chinese medicine injections.
10.19540/j.cnki.cjcmm.20200708.501
- Author:
Ya-Ling SONG
1
;
Ya-Lu WEN
2
;
Li ZHANG
1
;
Hong-Hui WU
2
;
Ju-Kai HUANG
1
;
Ting GUAN
1
;
Xiao-Hui YANG
2
Author Information
1. Dongfang Hospital, Beijing University of Chinese Medicine Beijing 100078, China.
2. Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
drug instruction;
drug interaction;
medication for special populations;
revision;
traditional Chinese medicine injection
- MeSH:
Drugs, Chinese Herbal;
Humans;
Injections;
Medicine, Chinese Traditional;
Syndrome
- From:
China Journal of Chinese Materia Medica
2021;46(7):1839-1845
- CountryChina
- Language:Chinese
-
Abstract:
According to the notice on revision of the instructions for traditional Chinese medicine injections(TCMIs) issued by the National Medical Products Administration(NMPA) from January 2006 to May 2020, the revised contents in the instructions for 29 varieties involved in the notice were sorted out, and the existing problems in the instructions for TCMIs were analyzed, so as to provide the basis for dynamic revision of the instructions. It was found that the revised items of instructions for 29 varieties all involved adverse reactions, contraindications and precautions, and warnings were added for 82.76% of 29 TCMIs preparations, indicating that all the revised contents were related to safety issues. In addition, 33.33% of the drugs risks mentioned in the precautions were not indicated in the adverse reactions; 82.76% instructions did not indicate drug interactions; 17.24% instructions lacked medication notes for special populations; 48.28% instructions did not indicate traditional Chinese medicine(TCM) syndromes of the main disease; 44.83% instructions did not indicate the type and stage of indication; and 86.21% instructions did not indicate the course of treatment. It could be concluded that the instructions for TCMIs have known risks of drugs that are not fully reflected in adverse reactions and the effective information is not comprehensive. The risk control measures proposed in the precautions need to have aftereffect evaluation and there is a lack of drug interactions and medications for special populations. As an important part of the full life-cycle management of drugs, the revision of instructions for TCMIs should be continuously improved to provide the basis for safe and reasonable application of TCMIs. Based on the above problems, it is proposed that the marketing license holder as the main body of the revision of instructions should actively carry out post-marketing basic and clinical research in accordance with the characteristics of TCM, combine the updated research with the guidance of TCM theory and improve the revision level of instructions for TCMIs to provide the basis for post-marketing evaluation.
